VideoHIVViral Hepatitis and Liver DiseaseEndogenous Biomarker Informed Approach to Assess Potential - Vikram Arya, PhD, FCPView Video
VideoHIVViral Hepatitis and Liver Disease#8 - Pharmacokinetics of First-line Tuberculosis Drugs in Pregnant (...) - Marije Van SchalkwykView Video
VideoHIVViral Hepatitis and Liver Disease#3 - Pharmacokinetics of the small interfering RNA (siRNA) JNJ-73763989 (...) - Thomas KakudaView Video
VideoHIVViral Hepatitis and Liver Disease#1Predicting Pharmacokinetics of Nirmatrelvir/Ritonavir in(...) - Erica LeertouwerView Video
VideoHIVViral Hepatitis and Liver DiseaseCurrent COVID-19 Therapies and Variants - Stefano Bonora, MDView Video
VideoHIVViral Hepatitis and Liver DiseaseEmerging Strategies for Treating and Preventing Monkeypox, Ruth Byrne, MDView Video
VideoHIVViral Hepatitis and Liver DiseaseCurrent Situation of HIV and Monkeypox in Catalonia - Pep Coll, MDView Video
VideoHIVViral Hepatitis and Liver Disease#4 A Phase 1 Drug-Drug Interaction Study to Investigate (...) - Myreen TomasView Video
VideoHIVViral Hepatitis and Liver DiseaseDDIs Relevant for COVID-19 Therapeutic Agents & Implementation Challenges - Fiona Marra, MPharm, MScView Video
VideoHIVViral Hepatitis and Liver Disease#2: Pharmacokinetics of sotrovimab, a monoclonal antibody for early treatment of mild-to-moderate COVID-19 - Asma El-ZailikView Video
VideoHIVViral Hepatitis and Liver DiseasePRO Healthcare Provider: Long-Acting Injectables for PrEP - Steve Taylor, MBChB, FRCP, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseCON Healthcare Provider: Oral Daily and/or On Demand PrEP - Laura Waters, MD, FRCPView Video
VideoHIVViral Hepatitis and Liver DiseaseSession 2: Discussion with the Audience | International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022View Video
VideoHIVViral Hepatitis and Liver DiseasePharmacology Considerations of Future ART/PrEP Regimens - Marta Boffito, MD, PhD, FRCPView Video
VideoHIVViral Hepatitis and Liver DiseaseRecent Developments in Antivirals Against Herpes Simplex Virus Infection - Scott H. James, MDView Video
VideoHIVViral Hepatitis and Liver DiseaseWhat’s on the Horizon for Direct Acting Antivirals for Hepatitis B? - Jennifer Kiser, PharmD, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseLong-acting Cabotegravir for Treatment and Prevention: When Are You Protected? - M. Boffito, MD, PhD, FRCPView Video
VideoHIVViral Hepatitis and Liver DiseaseLong-acting Cabotegravir for Treatment and Prevention - M. Boffito, MD, PhD, FRCPView Video
VideoHIVViral Hepatitis and Liver DiseaseThe Non-adherent Patient: A Good or Bad Candidate for CAB+RPV? - Jose Castillo-Mancilla, MDView Video
VideoHIVViral Hepatitis and Liver DiseaseAge-Related Changes in Pharmacokinetics and Pharmacodynamics - Catia Marzolini, PharmD, PhDView Video
VideoHIVViral Hepatitis and Liver DiseasePharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseOptimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals -Angela Colbers, PhDView Video
VideoHIVViral Hepatitis and Liver DiseasePharmacokinetics of mAbs in Prevention, Treatment and Cure of Viral Infections -Edmund Capparelli, PharmDView Video
VideoHIVViral Hepatitis and Liver DiseaseMultipurpose Prevention Technologies (MPTs) For Prevention of HIV and Pregnancy - Sharon L. Hillier, PhDView Video
VideoHIVViral Hepatitis and Liver DiseaseStrategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhDView Video
VideoHIVViral Hepatitis and Liver DiseasePoint of Care Tests for Drug Level Testing: Where Are We? - Paul K. Drain, MD, MPH, FIDSAView Video
VideoHIVViral Hepatitis and Liver DiseaseShort Talk: Islatravir Toxicity - Charles Flexner, MDView Video
VideoHIVViral Hepatitis and Liver DiseaseShort Talk: Cabotegravir/Rilpivirine Failures Despite Adherence - Jose Castillo-Mancilla, MDView Video
